Eli Lilly CEO David Ricks (Evan Vucci/AP Images)

Eli Lil­ly's David Ricks snared $24M pay pack­age in a year tur­bo-boost­ed by Covid-19 an­ti­body

Boost­ed by boom­ing sales of its Covid-19 an­ti­body bam­lanivimab, Eli Lil­ly post­ed dou­ble-dig­it growth in 2020 de­spite a more steady show­ing from its lega­cy port­fo­lio. In his fourth year at the helm, CEO David Ricks will tout 2020 as a win — par­tic­u­lar­ly for his pock­et­book.

Ricks se­cured $23.7 mil­lion in pay in 2020, a rough­ly 11% bump from the pre­vi­ous year, the In­di­anapo­lis drug­mak­er dis­closed in a proxy fil­ing with the SEC.

Most of that bump was tied to in­creas­es in Ricks’ pen­sion val­ue as well as his stock awards. The four-year helms­man snared $13.6 mil­lion in stock, or about $1.3 mil­lion more than 2019. Ricks’ base salary saw a small in­crease to $1.48 mil­lion — a lit­tle more than the $1.4 mil­lion flat he bagged in 2019.

In a year light on trav­el, Ricks al­so racked up about $40,000 in cor­po­rate air ex­pens­es, Lil­ly said, which in­cludes pay­ing the crew, fu­el­ing and “on-board cater­ing,” among oth­er fees.

It was a big year for Ricks as Lil­ly over­saw the de­vel­op­ment and com­mer­cial­iza­tion of LY-CoV5555 (bam­lanivimab), a Covid-19 an­ti­body that is one of few mol­e­cules ap­proved for emer­gency use in the US. On the year, bam­lanivimab snared $871 mil­lion in sales — near­ly a block­buster de­spite what has been less-than-stel­lar up­take for an­ti­bod­ies across the board.

With bam­lanivimab in the fold, Lil­ly saw a 10% in­crease in sales in 2020 to $24.54 mil­lion. But out­side of its an­ti­body, the pic­ture at Lil­ly is a lit­tle less clear. Bam­lanivimab not in­clud­ed, Lil­ly’s sales jumped just 6% on the year — well with­in range for Big Phar­ma but not quite the dou­ble-dig­it growth that catch­es eye­balls.

Anat Ashke­nazi

Ricks is al­so like­ly sting­ing from the ouster of his CFO Josh Smi­ley, who was kicked out of the com­pa­ny this month — and stripped of around $24 mil­lion in pay — for an “in­ap­pro­pri­ate mes­sages” scan­dal with oth­er em­ploy­ees. Lil­ly said Smi­ley will be “avail­able” to Ricks and new CFO Anat Ashke­nazi through Ju­ly of this year on re­duced bi­week­ly pay of $9,000. Lil­ly will still hold on to its 24-month non-so­lic­i­ta­tion agree­ment in Smi­ley’s con­tract as well as an 18-month non-com­pe­ti­tion pact.

Smi­ley was Ricks’ hand­picked ap­pointee for CFO back in 2017 as the then-new CEO looked to re­work Lil­ly’s stag­nant busi­ness plan. One of Lil­ly’s home­grown suc­cess sto­ries, Ricks start­ed on with the drug­mak­er back in 1996 as a busi­ness de­vel­op­ment as­so­ciate be­fore steadi­ly ris­ing through the ranks over the course of 25 years.

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

If you enjoy the People section in this report, you may also want to check out Peer Review, my colleagues Alex Hoffman and Kathy Wong’s comprehensive compilation of comings and goings in biopharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Demis Hassabis, DeepMind CEO (Qianlong/Imaginechina via AP Images)

Google's Deep­Mind opens its pro­tein data­base to sci­ence — po­ten­tial­ly crack­ing drug R&D wide open

Nearly a year ago, Google’s AI outfit DeepMind announced they had cracked one of the oldest problems in biology: predicting a protein’s structure from its sequence alone. Now they’ve turned that software on nearly every human protein and hundreds of thousands of additional proteins from organisms important to medical research, such as fruit flies, mice and malaria parasite.

The new database of roughly 350,000 protein sequences and structures represents a potentially monumental achievement for the life sciences, one that could hasten new biological insights and the development of new drugs. DeepMind said it will be free and accessible to all researchers and companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

In­side Bio­gen's scram­ble to sell Aduhelm: Pro­ject 'Javelin' and pres­sure to ID as many pa­tients as pos­si­ble

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment centers would administer the drug through a program called “Javelin,” a senior Biogen employee told Endpoints News.

The program identified about 800 centers for use, he said, and Biogen now pays for the use of bioassays to identify beta amyloid in potential patients having undergone a lumbar puncture procedure, the employee said — and one center preparing to administer the drug confirmed its participation in the bioassay program.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis dis­cards one of its ‘wild card’ drugs af­ter it flops in key study. But it takes one more for the hand

Always remember just how risky it is to gamble big on small studies.

A little more than 4 years ago, Novartis reportedly put up a package worth up to $1 billion for the dry eye drug ECF843 after a small biotech called Lubris put it through its paces in a tiny study of 40 moderate to severe patients, tracking some statistically significant markers of efficacy.

By last fall, the program had risen up to become one of CEO Vas Narasimhan’s top “wild card” programs in line for a potential breakthrough year in 2021. These drugs were all considered high-risk, high-reward efforts. And in this case, risk won.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

EMA re­jects FDA-ap­proved Parkin­son's drug, signs off on Mod­er­na vac­cine use in ado­les­cents ahead of FDA

The European Medicines Agency on Friday rejected Kyowa Kirin’s Parkinson’s disease drug Nouryant (istradefylline), which the US FDA approved in 2019 under the brand name Nourianz.

EMA said it considered that the results of the clinical studies used to support the application “were inconsistent and did not satisfactorily show that Nouryant was effective at reducing the ‘off’ time. Only four out of the eight studies showed a reduction in ‘off’ time, and the effect did not increase with an increased dose of Nouryant.”

6 top drug­mak­ers of­fer per­spec­tives on FDA's new co­vari­ates in RCTs guid­ance

Back in May, the FDA revised and expanded a 2019 draft guidance that spells out how to adjust for covariates in the statistical analysis of randomized controlled trials.

Building on the ICH’s E9 guideline on the statistical principles for clinical trials, the 3-page draft was transformed into an 8-page draft, with more detailed recommendations on linear and nonlinear models to analyze the efficacy endpoints in RCTs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Al Sandrock, Biogen R&D chief (Biogen via YouTube)

Bio­gen has a shaky end to H1 with a $542M write-off adding to its woes — but an­a­lysts see big rev­enue ahead for Aduhelm

All eyes at Biogen’s Q2 earnings call Thursday were on Aduhelm, but investors also got a glimpse of what Biogen would have faced had the FDA not opted to approve their controversial Alzheimer’s drug.

That glimpse, revealing a combination of declining sales, growing competition and failed medicines, underscores the stakes of the big biotech’s Aduhelm efforts, as execs punch back at the criticism they’ve engendered in the political and medical world and vigorously pushes its sales staff to roll out the drug as fast as possible.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Ken Frazier, Merck CEO (Bess Adler/Bloomberg via Getty Images)

Ex-Mer­ck chief Ken Fra­zier takes a lead­ing role in a $600M 'Health As­sur­ance' ven­ture fund

Ken Frazier has opened up a new chapter in his storied career.

The ex-Merck CEO is joining a high-minded venture group with plans to carve a unique role for itself at the well-traveled juncture of tech and life sciences. And the new job comes through an old college buddy.

Officially, Frazier now becomes chairman of General Catalyst’s health assurance initiative. Their $600 million fund was unveiled back in early April, planning to invest in companies that could push the “evolution from a ‘sick care’ system to a resilient, proactive Health Assurance system designed to help people stay well, bend the cost curve, and make quality care more affordable and more accessible to all.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,600+ biopharma pros reading Endpoints daily — and it's free.

Mol­e­c­u­lar Di­ag­nos­tics Can Trans­form Can­cer Care. Let’s Make It Hap­pen.

Like so many people around the world, my life has been profoundly shaped by cancer. Those personal experiences, along with a deep love of clinical laboratory science and a passion to apply the power of genomics in medicine, motivated me to launch a company that would improve cancer care through better diagnostics. Thirteen years later, I am proud that we are delivering more accurate information at multiple points along the patient journey, with a focus on eight of the 10 cancers that are most commonly diagnosed in the United States.